<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">SALMETEROL XINAFOATE</span><br/>(sal-me'ter-ol xin'a-fo-ate)<br/><span class="topboxtradename">Serevent<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">beta-adrenergic agonist (sympathomimetic)</span>; <span class="classification">bronchodilator</span>; <span class="classification">respiratory smooth muscle relaxant</span><br/><b>Prototype: </b>Albuterol<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mcg aerosol; 50 mcg powder diskus for inhalation</p>
<h1><a name="action">Actions</a></h1>
<p>Long-acting beta<sub>2</sub>-adrenoreceptor agonist and an analog of albuterol. Stimulation of beta<sub>2</sub>-adrenoreceptors relaxes bronchospasm and increases ciliary motility, thus facilitating expectoration. Inhibits the release
         of mediators (i.e., histamine) from mast cells, macrophages, and eosinophils.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Relaxes bronchospasm and increases ciliary motility, thus facilitating expectoration of pulmonary secretions. Salmeterol also
         decreases airway reaction to allergens.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Maintenance therapy for asthma or bronchospasm. Prevention of exercise-induced bronchospasm. Do not use to treat acute bronchospasm.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to salmeterol; primary treatment of status asthmaticus; pregnancy (category C), lactation; safety and efficacy
         in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Cardiovascular disorders, cardiac arrhythmias, hypertension; history of seizures or thyrotoxicosis; liver and renal impairment,
         older adults, diabetes mellitus, sensitivity to other beta-adrenergic agonists; women in labor.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Asthma or Bronchospasm</span><br/><span class="rdage">Adult/</span><span class="rdage">Child: <img src="../images/special/greaterorequal.gif"/>4 y:</span> <span class="rdroute">Inhalation</span> 2 inhalations of aerosol (42 mcg) or 1 powder diskus (50 mcg) b.i.d. approximately 12 h apart<br/><br/><span class="indicationtitle">Prevention of Exercise-Induced Bronchospasm</span><br/><span class="rdage">Adult/</span><span class="rdage">Child: <img src="../images/special/greaterorequal.gif"/>4 y:</span> <span class="rdroute">Inhaled</span> 2 inhalations of aerosol (42 mcg) or 1 powder diskus (50 mcg) 3060 min before exercise<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Inhalation</span><br/><ul>
<li>Do not use to relieve symptoms of acute asthma.</li>
<li>Shake canister well before using; close lips tightly around the mouthpiece, and patient inhales deeply during each actuation.</li>
<li>Store at room temperature, 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, headache, tremor. <span class="typehead">CV:</span> Palpitations, sinus tachycardia. <span class="typehead">Respiratory:</span> <span class="speceff-life">Respiratory arrest</span> (rare). <span class="typehead">Skin:</span> Rash. <span class="typehead">Body as a Whole:</span> Tolerance (tachyphylaxis). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Effects antagonized by <span class="classification">beta blockers</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 1020 min. <span class="typehead">Peak:</span> Effect 2 h. <span class="typehead">Duration:</span> Up to 12 h. <span class="typehead">Distribution:</span> 9495% protein bound. <span class="typehead">Metabolism:</span> Dissociates in solution; salmeterol base and xinafoate salt are metabolized, absorbed, distributed, and excreted independently;
      salmeterol is extensively metabolized by hydroxylation. <span class="typehead">Elimination:</span> Eliminated primarily in feces. <span class="typehead">Half-Life:</span> 34 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Withhold drug and notify physician immediately if bronchospasms occur following its use.</li>
<li>Monitor cardiovascular status; report tachycardia.</li>
<li>Monitor liver enzymes periodically with long-term therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician immediately of worsening asthma or failure to respond to the usual dose of salmeterol.</li>
<li>Do not use an additional dose prior to exercise if taking twice-daily doses of salmeterol.</li>
<li>Take the preexercise dose 3060 min before exercise and wait 12 h before an additional dose.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>